[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 141,278
  • Shares Outstanding, K 57,901
  • Annual Sales, $ 66,800 K
  • Annual Income, $ 8,570 K
  • EBIT $ 6 M
  • EBITDA $ 6 M
  • 60-Month Beta 1.43
  • Price/Sales 2.20
  • Price/Cash Flow 16.76
  • Price/Book 2.43

Options Overview Details

View History
  • Implied Volatility 134.80% (+28.81%)
  • Historical Volatility 47.59%
  • IV Percentile 56%
  • IV Rank 7.13%
  • IV High 1,123.49% on 05/15/25
  • IV Low 58.84% on 05/04/26
  • Expected Move (DTE 1) 0.28 (11.50%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 626
  • Volume Avg (30-Day) 483
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 14,935
  • Open Int (30-Day) 12,789
  • Expected Range 2.16 to 2.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) +262,994.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.41 +1.24%
on 05/05/26
2.92 -16.58%
on 04/22/26
-0.34 (-12.23%)
since 04/13/26
3-Month
2.11 +15.64%
on 03/03/26
2.92 -16.58%
on 04/22/26
+0.05 (+2.09%)
since 02/13/26
52-Week
0.63 +288.72%
on 05/15/25
3.22 -24.22%
on 07/09/25
+1.75 (+253.62%)
since 05/13/25

Most Recent Stories

More News
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 Spero maintains its...

SPRO : 2.44 (-3.94%)
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for...

SPRO : 2.44 (-3.94%)
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025 In February, Spero’s...

SPRO : 2.44 (-3.94%)
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for...

SPRO : 2.44 (-3.94%)
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare...

SPRO : 2.44 (-3.94%)
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for...

SPRO : 2.44 (-3.94%)
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025 Spero’s development partner, GSK, plans...

SPRO : 2.44 (-3.94%)
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for...

SPRO : 2.44 (-3.94%)
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment 1 Data will be...

SPRO : 2.44 (-3.94%)
GSK : 50.99 (+0.18%)
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare...

SPRO : 2.44 (-3.94%)

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 2.66
2nd Resistance Point 2.61
1st Resistance Point 2.53
Last Price 2.44
1st Support Level 2.39
2nd Support Level 2.34
3rd Support Level 2.26

See More

52-Week High 3.22
Last Price 2.44
Fibonacci 61.8% 2.23
Fibonacci 50% 1.92
Fibonacci 38.2% 1.62
52-Week Low 0.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.